Bionomics

Agilex Biolabs Congratulates Bionomics Limited on BNC210 PK Results

Friday, April 30, 2021 - 5:00am

b'ADELAIDE, AUS, Apr 30, 2021 - (ACN Newswire) - Agilex Biolabs, Australia\'s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, today congratulated client Bionomics Limited (Bionomics) on its positive pharmacokinetic (PK) results from a 7-day dosing study in healthy volunteers using the newly developed solid dose oral tablet formulation of BNC210.\nLiz Doolin, Bionomics\' Vice President Clinical Development commented that "We greatly value our long-standing partnership with Agilex Biolabs who continue to be a partner of choice for Bionomics and have supported the development of BNC210 from the beginning.

Key Points: 
  • b'ADELAIDE, AUS, Apr 30, 2021 - (ACN Newswire) - Agilex Biolabs, Australia\'s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, today congratulated client Bionomics Limited (Bionomics) on its positive pharmacokinetic (PK) results from a 7-day dosing study in healthy volunteers using the newly developed solid dose oral tablet formulation of BNC210.\nLiz Doolin, Bionomics\' Vice President Clinical Development commented that "We greatly value our long-standing partnership with Agilex Biolabs who continue to be a partner of choice for Bionomics and have supported the development of BNC210 from the beginning.
  • "\nBionomics (ASX: BNO, OTCQB: BNOEF, Germany: AU000000BNO5), is a global, clinical stage biopharmaceutical company.
  • Agilex Biolabs has been working closely with Bionomics for several years, supporting the PK regulated Bioanalysis of BNC210 and is privileged to be a part of this potential new treatment for anxiety and stressor-related disorders.
  • Australian clinical trials have remained open for business and Agilex Biolabs is a designated essential service so clients can be assured of study continuity.

Novamind Announces Strategic Investment in Bionomics to Support PTSD Clinical Trial

Thursday, February 11, 2021 - 12:00pm

In addition, Cedar Clinical Research ("CCR"), a wholly owned subsidiary of Novamind based in Springville, Utah, will be evaluated by Bionomics as a clinical research site to conduct Bionomics' Phase IIb trial examining BNC210.

Key Points: 
  • In addition, Cedar Clinical Research ("CCR"), a wholly owned subsidiary of Novamind based in Springville, Utah, will be evaluated by Bionomics as a clinical research site to conduct Bionomics' Phase IIb trial examining BNC210.
  • Novamind's Strategic Investment is included in Bionomics' latest round of financing, which was underwritten by Apeiron Investments and received commitments for AU$16,000,000 (approximately CAN$15,680,000, the "Bionomics Financing").
  • Proceeds from the Bionomics Financing will support the initiation of a Phase IIb trial for BNC210, planned for mid-2021.
  • "I'm happy to welcome Novamind as a strategic investor in Bionomics," said Dr. Errol De Souza, Executive Chairman of Bionomics.

DGAP-News: Novamind Inc.: Novamind Announces Strategic Investment in Bionomics to Support PTSD Clinical Trial

Thursday, February 11, 2021 - 1:12pm

In addition, Cedar Clinical Research ("CCR"), a wholly owned subsidiary of Novamind based in Springville, Utah, will be evaluated by Bionomics as a clinical research site to conduct Bionomics' Phase IIb trial examining BNC210.

Key Points: 
  • In addition, Cedar Clinical Research ("CCR"), a wholly owned subsidiary of Novamind based in Springville, Utah, will be evaluated by Bionomics as a clinical research site to conduct Bionomics' Phase IIb trial examining BNC210.
  • Novamind's Strategic Investment is included in Bionomics' latest round of financing, which was underwritten by Apeiron Investments and received commitments for AU$16,000,000 (approximately CAN$15,680,000, the "Bionomics Financing").
  • Proceeds from the Bionomics Financing will support the initiation of a Phase IIb trial for BNC210, planned for mid-2021.
  • "I'm happy to welcome Novamind as a strategic investor in Bionomics," said Dr. Errol De Souza, Executive Chairman of Bionomics.

Recapitalisation Led by Sophisticated Life Sciences Investor - Apeiron Investment Group Ltd

Tuesday, June 2, 2020 - 11:00am

Upon satisfaction of Aperions underwriting obligations, and subject to the Company raising the additional A$15,000,000, Apeiron will be granted 150,000,000 Warrants.

Key Points: 
  • Upon satisfaction of Aperions underwriting obligations, and subject to the Company raising the additional A$15,000,000, Apeiron will be granted 150,000,000 Warrants.
  • Every one Warrant grants Apeiron the right to be issued one further Share in Bionomics at an exercise price of A$0.06.
  • Bionomics Executive Chairman Dr Errol De Souza said We are pleased to have secured the support of a world-class and like-minded life science investor of the quality of Apeiron.
  • Through Apeiron, I support numerous promising drug candidates, for example the psychedelics being developed by my biotech platform ATAI Life Sciences.